Metformin-treated patients with diabetes who were on adjuvant chemotherapy for triple-negative breast cancer had an overall survival rate of 67%, while those in the nontreated and no-diabetes groups had 69% and 66% OS rates respectively, a study in Cancer found. The findings, however, did suggest a lower risk of developing distant metastasis in diabetic patients taking metformin compared with nondiabetic patients, the researchers said.

Related Summaries